Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 13/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 12/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL354004 | 0.94 | HTT (0.49) | ROCK1ROCK2HTTATG4BKMT2A | |
| SCHEMBL351593 | 0.92 | ROCK2 (0.49) | ROCK1ROCK2ATG4BKMT2AMEN1 | |
| SCHEMBL355123 | 0.90 | ROCK2 (0.51) | ROCK1ROCK2ATG4BKMT2AMEN1 | |
| SCHEMBL352833 | 0.89 | ROCK2 (0.49) | ROCK1ROCK2ATG4BKMT2AMEN1 | |
| SCHEMBL353432 | 0.88 | ROCK2 (0.49) | ROCK1ROCK2HTTATG4BKMT2A | |
| SCHEMBL19118745 | 0.87 | ROCK1 (0.47) | ROCK1ROCK2ATG4BKMT2AMEN1 | |
| SCHEMBL352392 | 0.84 | ROCK1 (0.47) | ROCK1ROCK2ATG4BKMT2AMEN1 | |
| SCHEMBL352935 | 0.84 | ROCK2 (0.48) | ROCK1ROCK2ATG4BKMT2AMEN1 | |
| SCHEMBL353559 | 0.83 | ROCK2 (0.52) | ROCK1ROCK2ATG4BKMT2AMEN1 | |
| SCHEMBL354050 | 0.83 | ROCK1 (0.54) | ROCK1ROCK2ATG4BEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716320-B2 | Antibacteriall heterocyclic ureas | REPLIDYNE, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20080207703-A1 | Antibacterial heterocyclic ureas | REPLIDYNE, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| WO-2008011191-A1 | ANTIBACTERIAL HETEROCYCLIC UREAS | REPLIDYNE, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207703-A1 | Antibacterial heterocyclic ureas | UMPS, UROD, UGP2 | ROCK1 4331/4885ROCK2 4405/4885HTT 1028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.